LDK378: a promising anaplastic lymphoma kinase (ALK) inhibitor.
about
ALK-positive non-small cell lung cancer: mechanisms of resistance and emerging treatment optionsUnderstanding the Interplay between Expression, Mutation and Activity of ALK Receptor in Rhabdomyosarcoma Cells for Clinical Application of Small-Molecule InhibitorsALK inhibitors in non-small cell lung cancer: crizotinib and beyond.Prevalence and natural history of ALK positive non-small-cell lung cancer and the clinical impact of targeted therapy with ALK inhibitorsPF-06463922, an ALK/ROS1 Inhibitor, Overcomes Resistance to First and Second Generation ALK Inhibitors in Preclinical ModelsSynthesis of a [(18)F]-labeled ceritinib analogue for positron emission tomography of anaplastic lymphoma kinase, a receptor tyrosine kinase, in lung cancer.Molecular analysis of cell-free circulating DNA for the diagnosis of somatic mutations associated with resistance to tyrosine kinase inhibitors in non-small-cell lung cancer.Targeted therapy for non-small cell lung cancer: current standards and the promise of the future.Mechanisms of Acquired Resistance to ALK Inhibitors and the Rationale for Treating ALK-positive Lung Cancer.Anaplastic lymphoma kinase: Role in cancer and therapy perspective.Spotlight on ceritinib in the treatment of ALK+ NSCLC: design, development and place in therapy.Overcoming crizotinib resistance in ALK-rearranged NSCLC with the second-generation ALK-inhibitor ceritinib.Effects of SMYD2-mediated EML4-ALK methylation on the signaling pathway and growth in non-small-cell lung cancer cells.ALK inhibitor resistance in ALK(F1174L)-driven neuroblastoma is associated with AXL activation and induction of EMT.Overcoming drug-tolerant cancer cell subpopulations showing AXL activation and epithelial-mesenchymal transition is critical in conquering ALK-positive lung cancer.[Advances of driver gene and targeted therapy of non-small cell lung cancer].
P2860
Q26820845-66B3B9AF-F217-4DF3-827E-E1063C3879C9Q28546245-AE88975C-214C-459F-B4D9-AEB70BE21507Q34431889-1F9D7B96-9C1B-40BC-86A9-3B446BD2C800Q34564071-CB0A2D93-68A2-4745-98FD-25909F7AD7BFQ35858617-0E3B12EF-ACE9-4811-8788-BDA23C17B553Q36890803-89EDF4E6-41AB-4564-A1E4-68EB91E284B6Q38203956-55650CC0-B859-47A8-A4EA-0FC61D8FC071Q38390200-E8A00276-FD08-4CA9-B891-F5EBAF2DA54FQ38459398-6602722E-AB83-4D32-8A3B-77D89A25482FQ38623421-522A9CF7-B1F2-4A16-A9CC-0259F3E0850CQ38663460-91830578-FB39-4FDA-A0A0-28AA0E9768D1Q38665438-F640F04E-12A1-4AD3-AB50-F8CF0C29F9FCQ41072068-20800A2D-A154-44C4-A42E-1C4FF1E25581Q42572358-60044548-0DEA-49B3-B54E-F32BBBF4BE28Q55280343-7B137D58-281E-4338-8D54-328BF4DA9E03Q55465064-F5906CA9-91C6-427E-A3B9-77E6713F5C46
P2860
LDK378: a promising anaplastic lymphoma kinase (ALK) inhibitor.
description
2013 nî lūn-bûn
@nan
2013年の論文
@ja
2013年学术文章
@wuu
2013年学术文章
@zh
2013年学术文章
@zh-cn
2013年学术文章
@zh-hans
2013年学术文章
@zh-my
2013年学术文章
@zh-sg
2013年學術文章
@yue
2013年學術文章
@zh-hant
name
LDK378: a promising anaplastic lymphoma kinase (ALK) inhibitor.
@en
LDK378: a promising anaplastic lymphoma kinase
@nl
type
label
LDK378: a promising anaplastic lymphoma kinase (ALK) inhibitor.
@en
LDK378: a promising anaplastic lymphoma kinase
@nl
prefLabel
LDK378: a promising anaplastic lymphoma kinase (ALK) inhibitor.
@en
LDK378: a promising anaplastic lymphoma kinase
@nl
P2093
P356
P1476
LDK378: a promising anaplastic lymphoma kinase (ALK) inhibitor.
@en
P2093
Cheng Jiang
Jianyong Chen
Shaomeng Wang
P304
P356
10.1021/JM401005U
P407
P577
2013-07-09T00:00:00Z